Harnessing Innovations in Vector Technology for Improved Delivery to the CNS & Addressing Core Market Access Challenges to Deliver Safe, Efficacious & Commercially Successful Gene Therapies for Neurological Disorders in Europe
6 - 8 June | Amsterdam, Netherlands
Welcome to the 4th Annual Gene Therapy for Neurological Disorders Summit Europe
Delivering Lifechanging Gene Therapies to the CNS
The Gene Therapy for Neurological Disorders Summit is back as Europe’s exclusive meeting focussed on innovations in gene therapy vectors for CNS delivery, and as the only event to cover Eurocentric challenges facing gene therapy developers.
Recent years have been turbulent for the gene therapy field, but with recent approvals like Upstaza and Skysona, the future is looking bright for CNS gene therapies.
This June will see 80+ drug developers working in gene therapy for neurological disorders united with the shared goal of overcoming preclinical translatability, clinical, delivery and market access challenges to help get life changing gene therapies to patients faster in Europe.
World-Class Speaker Faculty Included:
Chief Scientific Officer
Vice President & Head Of Central Nervous System Sector & Neurobiology Lead
Executive Director - Research & Development & Prevail Therapeutics
Eli Lilly & Co.
"A great opportunity to network within the CNS gene therapy community" – Sue Brown, Passage Bio